Sun Pharma and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.
source https://www.pharmatutor.org/pharma-news/2020/sun-pharma-announces-japan-mhlw-approval-of-ilumyatm-for-the-treatment-of-plaque-psoriasis
No comments:
Post a Comment